Here's How Moderna Is Ensuring Its Lead in the Coronavirus Vaccine Market
A product that generates about $200,000 in quarterly sales may not sound too exciting. But what if I told you that product was on the market for only two weeks in that quarter? And what if this product was a particular company's first ever to reach commercialization? Now it's probably starting to sound impressive.
As you might have guessed (thanks to the headline of this article), I'm referring to Moderna (NASDAQ: MRNA) and its coronavirus vaccine. Clearly, Moderna investors have reason to cheer. But the most important points in the recent earnings report don't have to do with earnings. Instead they're elements that show us how Moderna may stay ahead of rivals in this increasingly competitive market. The U.S. Food and Drug Administration (FDA) granted Johnson & Johnson (NYSE: JNJ) Emergency Use Authorization (EUA) for its single-dose vaccine on Feb. 27. And Novavax (NASDAQ: NVAX) expects to report data from the U.S. phase 3 trial of its potential vaccine in the coming weeks. Let's take a look at why, despite new market entrants, Moderna still is likely to hold on to a big share of the vaccine market.
Image source: Getty Images.
Source Fool.com
